Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 350 of 866 entries
View as:

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Phase: N/A Priority: Normal
NCT ID: NCT06468228 Org: User:
Start: 06/27/24 End: 12/31/26 Due: 12/31/27

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Phase: N/A Priority: Normal
NCT ID: NCT05609630 Org: User:
Start: 10/02/23 End: 06/30/29 Due: 06/30/30

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Phase: N/A Priority: Normal
NCT ID: NCT04524611 Org: User:
Start: 09/30/20 End: 02/15/28 Due: 02/15/29

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Phase: N/A Priority: Normal
NCT ID: NCT06389136 Org: User:
Start: 06/12/24 End: 03/31/27 Due: 03/31/28

An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

Phase: N/A Priority: Normal
NCT ID: NCT02082197 Org: User:
Start: 03/31/14 End: 06/30/15 Due: 06/30/16

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02210663 Org: User:
Start: 07/31/14 End: 07/31/16 Due: 07/31/17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Phase: N/A Priority: Normal
NCT ID: NCT06158854 Org: User:
Start: 04/01/24 End: 02/29/28 Due: 02/28/29

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03441555 Org: User:
Start: 05/30/18 End: 01/25/21 Due: 01/25/22

A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD)

Phase: N/A Priority: Normal
NCT ID: NCT04262791 Org: User:
Start: 02/17/20 End: 01/31/22 Due: 01/31/23

A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05316233 Org: User:
Start: 05/02/22 End: 09/12/24 Due: 09/12/25

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

Phase: N/A Priority: Normal
NCT ID: NCT05782907 Org: User:
Start: 11/06/23 End: 10/31/33 Due: 10/31/34

Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Phase: N/A Priority: Normal
NCT ID: NCT01834638 Org: User:
Start: 03/31/13 End: 11/30/14 Due: 11/30/15

Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03415035 Org: User:
Start: 03/09/18 End: 06/30/26 Due: 06/30/27

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Phase: N/A Priority: Normal
NCT ID: NCT03978520 Org: User:
Start: 07/25/19 End: 07/14/22 Due: 07/14/23

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

Phase: N/A Priority: Normal
NCT ID: NCT03219216 Org: User:
Start: 06/06/18 End: 03/11/19 Due: 03/11/20

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03639194 Org: User:
Start: 10/24/18 End: 01/25/24 Due: 01/25/25

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03922607 Org: User:
Start: 06/11/19 End: 04/13/21 Due: 04/13/22

Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05274100 Org: User:
Start: 09/01/20 End: 07/06/21 Due: 07/06/22

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

Phase: N/A Priority: Normal
NCT ID: NCT02443298 Org: User:
Start: 06/23/15 End: 02/02/18 Due: 02/02/19

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03400306 Org: User:
Start: 11/15/21 End: 11/16/21 Due: 11/16/22

Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02611713 Org: User:
Start: 01/04/16 End: 12/24/20 Due: 12/24/21

Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)

Phase: N/A Priority: Normal
NCT ID: NCT02582658 Org: User:
Start: 10/06/15 End: 01/12/17 Due: 01/12/18

A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT06794866 Org: User:
Start: 01/22/25 End: 08/31/26 Due: 08/31/27

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

Phase: N/A Priority: Normal
NCT ID: NCT01889186 Org: User:
Start: 06/27/13 End: 12/15/20 Due: 12/15/21

The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland

Phase: N/A Priority: Normal
NCT ID: NCT02582671 Org: User:
Start: 11/05/15 End: 11/29/17 Due: 11/29/18